The present study was therefore designed to investigate hemostasis mechanisms associated with the use of conventional BPAs (rFVIIa and aPCC), pd-FVIIa/FX, or FX in an AT-reduced plasma model (fitusiran-treated) of people with hemophilia. Here, F10 is linked to hemophilia.